Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB has announced the appointment of its Nomination Committee in preparation for the Annual General Meeting (AGM) 2026. The committee, comprising representatives from the three largest shareholders and the chairman of the Board, is tasked with proposing candidates for board positions and determining remuneration, reflecting the company’s commitment to transparent governance and stakeholder engagement.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to promote anti-inflammatory effects and help patients achieve immune balance.
Average Trading Volume: 148,255
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.1B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.